SITE005-0104

SITE005 (FRA) › SITE005-0104

SITE005-0104

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2026-01-03

enrolled

AEs

2

Serious

1

Dropout signal

–

Adverse events

2

Grade 2 Hyperthyroidism — outcome: RECOVERED/RESOLVED; onset 2022-09-21 (study day 68); relationship: not assessed

moderate assessed

Grade 3 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-08-24 (study day 40); relationship: not assessed; serious criteria: hospitalization

severe serious assessed

Data queries

0

No data queries. Open queries would appear here for this patient.